Cone Biopsy of the Cervix (Conization): Procedure, Recovery & Outcomes — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cone biopsy of the cervix, also called cervical conization, is a gynaecological surgical procedure in which a cone-shaped segment of cervical tissue is surgically removed for histopathological examination. The specimen includes the transformation zone — the area where columnar cervical cells meet squamous vaginal cells and where cervical precancerous changes most commonly arise — along with a margin of normal surrounding tissue and the lower endocervical canal. By removing this region, conization simultaneously provides a definitive tissue diagnosis and, in most cases, treats the abnormal cervical cells in a single procedure.

Conization is indicated when colposcopy-directed biopsies reveal high-grade cervical intraepithelial neoplasia (CIN 2 or CIN 3), cervical glandular intraepithelial neoplasia (CGIN), or when the upper limit of the transformation zone is not visible colposcopically (unsatisfactory colposcopy), when there is discordance between cytology and histology, or when microinvasive cervical carcinoma must be excluded. In microinvasive cervical cancer (FIGO stage IA1), cone biopsy with clear margins may be considered definitive surgical treatment, preserving fertility.

Three primary techniques exist: large loop excision of the transformation zone (LLETZ), also termed loop electrosurgical excision procedure (LEEP) in North America; cold-knife conization (CKC); and laser conization. LLETZ is the most widely performed technique globally due to its outpatient applicability, speed, and acceptable histological specimen quality. Global access to conization as part of cervical screening and prevention programmes is a public health priority endorsed by the WHO, which recommends screen-and-treat strategies in low-resource settings using LLETZ as the treatment modality of choice.

Cone biopsy is used for diagnosis and treatment of the following cervical conditions:

• CIN 2 (moderate cervical dysplasia): Pre-cancerous changes in the middle third of the cervical epithelium; treatment is recommended for persistent CIN 2 (not regressing after 12–24 months of surveillance) and routinely in women over 25 years
• CIN 3 (severe cervical dysplasia / carcinoma in situ): Full-thickness involvement of the cervical epithelium; high risk of progression to invasive cancer if untreated — excision is mandatory
• Cervical glandular intraepithelial neoplasia (CGIN): Pre-cancerous changes in glandular (columnar) cervical cells; requires cold-knife or laser cone to achieve adequate endocervical margin assessment due to skip lesion pattern
• Microinvasive cervical carcinoma (FIGO stage IA1 and IA2): Early invasive cancer confined to the cervical stroma; cone biopsy with clear margins may be curative for IA1 and fertility-sparing option in IA2 with negative lymph nodes
• Discordant cytology and histology: When cervical smear (Pap test) or HPV-based screening suggests high-grade disease but colposcopy-directed biopsy is low-grade or normal, a diagnostic cone biopsy reconciles the discrepancy
• Unsatisfactory colposcopy: When the entire transformation zone cannot be visualised colposcopically (type 3 transformation zone), a diagnostic excisional procedure is required to examine the endocervical canal
• Recurrent abnormal cervical cytology following previous ablative treatment: Patients who have undergone laser ablation or cryotherapy for CIN and develop further high-grade abnormalities require excisional (not ablative) treatment

Cone biopsy is appropriate for the following patients — eligibility assessment is made by a gynaecologist or colposcopist following full cervical screening evaluation:

• Women with confirmed CIN 2 or CIN 3 on colposcopy-directed biopsy: The primary indication; age, parity, and desire for future fertility influence the choice of technique but not the decision to treat
• Women with CGIN on cervical smear or directed biopsy: Excisional treatment (preferably CKC) is mandatory as CGIN cannot be adequately assessed or treated by ablation
• Women with unsatisfactory colposcopy: Where the squamocolumnar junction extends into the endocervical canal and cannot be fully seen, excision is required for adequate diagnosis
• Women with persistent smear abnormality and negative colposcopy: Diagnostic conization resolves unexplained high-grade cytological abnormalities when colposcopy is unrevealing
• Pregnancy: Cone biopsy during pregnancy is generally avoided unless invasive cancer must be excluded; diagnostic cone can be performed in the second trimester when absolutely necessary, accepting higher risk of haemorrhage and miscarriage
• Previous treatment failure: Women with CIN persisting or recurring after previous ablative or excisional treatment are eligible for repeat LLETZ or cold-knife cone
• General fitness: LLETZ under local anaesthesia is suitable for virtually all non-pregnant women; CKC requires general or spinal anaesthesia and fitness assessment accordingly

Three principal techniques are used for cervical conization, each with specific indications, advantages, and limitations:

• LLETZ (Large Loop Excision of the Transformation Zone) / LEEP: The most common technique worldwide. A thin wire loop carrying a high-frequency diathermy current is used to excise the transformation zone under colposcopic guidance. The loop is passed through the cervix in one or two passes ('see and treat' approach) under local anaesthetic infiltration. Procedure time is typically 5–10 minutes. The main advantage is outpatient performance under local anaesthesia; the main limitation is thermal artefact at excision margins that may compromise histological assessment.
• Cold-knife conization (CKC): The traditional surgical technique using a scalpel rather than electrocautery. A speculum is inserted, the cervix visualised, and a scalpel used to excise a cone of tissue — typically under general or spinal anaesthesia in an operating theatre. The primary advantage is superior specimen quality with minimal thermal artefact, making it the preferred technique for CGIN (due to skip lesions requiring clear endocervical margins), suspected microinvasive cancer, and cases where LLETZ thermal damage would compromise margin assessment. Haemorrhage risk is higher than LLETZ, necessitating haemostatic sutures or diathermy.
• Laser conization: CO2 laser used to vaporise or excise the transformation zone with precise tissue ablation and minimal thermal spread. Provides excellent specimen quality comparable to CKC. Used in centres with appropriate laser expertise; less widely available than LLETZ.
• Technique selection guide:
  • CIN 2/3 with satisfactory colposcopy: LLETZ is first choice
  • CGIN, unsatisfactory colposcopy, suspected microinvasion, previous LLETZ failure: cold-knife cone preferred
  • Fertility-sparing consideration: LLETZ preserves cervical length better than deep CKC cones

After excision, the specimen is oriented, inked, and submitted to pathology in formalin. The endocervical and ectocervical margins are assessed and reported. The endocervical margin status is the most clinically significant: a positive endocervical margin indicates higher risk of residual disease and influences follow-up strategy.

Cone biopsy of the cervix offers definitive diagnostic and therapeutic benefits:

• High cure rate for CIN: A single LLETZ procedure achieves complete excision (negative margins) in approximately 80–90% of cases; the overall cure rate for CIN 2/3 following excisional treatment is approximately 90–95% at 12-month follow-up
• Simultaneous diagnosis and treatment: In most cases, a single outpatient procedure under local anaesthesia both confirms the histological diagnosis and removes all abnormal tissue — eliminating the need for a separate surgery
• Fertility preservation: Unlike hysterectomy, conization preserves the uterus; with careful technique, a single LLETZ does not significantly increase the risk of preterm birth; deep cones or repeat excisions carry incrementally higher risk of cervical incompetence
• Cancer exclusion and staging: Cold-knife cone provides the optimal specimen for excluding or confirming microinvasive cervical cancer — a critical diagnostic distinction that determines whether simple excision or lymph node dissection is required
• Reduced long-term cancer risk: Successful treatment of CIN 3 reduces subsequent risk of cervical cancer by approximately 95%; women remain at slightly higher lifetime risk than the general population and require ongoing HPV-based surveillance
• Rapid recovery: Most women treated with LLETZ return to normal activities within 1–2 days and to work the following day; full healing occurs in 4–6 weeks

Cone biopsy is generally safe, especially LLETZ under local anaesthesia. Recognised risks include:

• Primary haemorrhage: Intraoperative bleeding is uncommon with LLETZ (diathermy achieves haemostasis) but is more likely with CKC; managed with diathermy, topical haemostatic agents (Monsels solution, silver nitrate), or absorbable sutures
• Secondary haemorrhage: Delayed bleeding 7–14 days post-procedure (coinciding with healing eschar separation) occurs in approximately 2–5% of cases; most settle with conservative management or re-diathermy in clinic, rarely requiring hospital admission or blood transfusion
• Infection: Cervical or uterine infection (endometritis) following the procedure; presenting as offensive vaginal discharge, fever, or pelvic pain; treated with antibiotics
• Cervical stenosis: Scarring of the cervical os causing narrowing; can result in menstrual outflow obstruction (haematometra) or difficulty with future colposcopy; higher risk with deep or repeat excisions
• Preterm birth risk: Well-documented association between cone biopsy and increased risk of preterm birth in subsequent pregnancies — relative risk approximately 1.5–2.0 times baseline; risk correlates with depth of excision; women planning pregnancy should discuss this with their gynaecologist
• Positive margins and residual disease: Positive endocervical margins do not mandate immediate re-excision but require closer surveillance (test of cure at 6 months); approximately 15–20% of positive-margin cases have residual CIN at re-examination
• Vasovagal reaction: During LLETZ under local anaesthesia, some women experience lightheadedness or faintness from cervical stimulation; managed with positioning and observation; resolves rapidly

Recovery after LLETZ is generally straightforward; CKC recovery is slightly longer. Post-procedure care and surveillance are as follows:

• Immediate post-procedure: After LLETZ, patients rest in clinic for 15–30 minutes post-procedure; light spotting and watery/blood-stained discharge is normal for 2–4 weeks as the treatment site heals and the eschar sloughs
• Activity restrictions (4 weeks): Avoid sexual intercourse, tampons, and vaginal douching for 4 weeks to reduce risk of infection and haemorrhage; baths and showering are acceptable; light exercise can resume after 24–48 hours; swimming and heavy exercise after 2 weeks
• Warning signs: Heavy bleeding (soaking more than one pad per hour), offensive discharge, fever above 38°C, or severe pelvic pain require prompt medical review
• Histopathology results: Available within 2–3 weeks; the treating colposcopist or gynaecologist will discuss margin status, CIN grade, and implications
• Test of cure (TOC): A co-test (HPV test + liquid-based cytology) is performed at 6 months post-treatment. HPV-negative result at TOC confers excellent reassurance of treatment success; patients then return to routine screening intervals. HPV-positive result at TOC requires repeat colposcopy.
• Long-term surveillance: Following successful treatment, women should remain in annual HPV testing for 3–5 years before returning to the standard 5-yearly screening interval. All treated women have a slightly elevated lifetime risk of cervical cancer and should not stop cervical screening after treatment.
• CKC post-operative care: Women undergoing CKC under general anaesthesia are typically discharged the same day or following morning; activity restriction is similar; cervical sutures, if placed, are absorbable

The cost of cone biopsy varies by technique, country, setting, and whether the procedure is performed as part of a national screening programme:

• United States: $1,500–$5,000 for LLETZ/LEEP in an outpatient setting; $4,000–$10,000 for cold-knife cone under general anaesthesia including operating theatre and anaesthesiologist fees; widely covered by insurance when medically indicated
• United Kingdom: Provided free under NHS for all colposcopy-referred women; private LLETZ: £800–£1,800; private CKC: £2,500–£5,000
• India: $200–$600 for LLETZ at accredited hospitals; $500–$1,500 for CKC — a fraction of US/UK costs with equivalent quality at JCI-accredited centres
• Thailand: $400–$1,200 for LLETZ; $1,000–$2,500 for CKC at international hospitals in Bangkok and Chiang Mai
• Turkey: $300–$900 for LLETZ; $800–$2,000 for CKC; widely available at private university hospitals
• Cost factors specific to cone biopsy:
  • Technique: LLETZ (lowest cost) vs. CKC (higher — requires general anaesthesia and operating theatre)
  • Histopathology fees: assessed separately, included at most international hospitals
  • Pre-operative colposcopy and cervical smear: typically required before conization and may be billed separately
  • Post-operative test of cure (co-test at 6 months): additional cost if not covered by insurance

The following alternatives to excisional cone biopsy may be considered depending on the clinical indication, CIN grade, and patient factors:

• Ablative treatments (for CIN 2/3 with satisfactory colposcopy only):
  • Cryotherapy: Freezing of the transformation zone with nitrous oxide or CO2; effective for CIN 1–2 with small lesions and no endocervical extension; used in low-resource settings; provides no histological specimen
  • Laser ablation: CO2 laser vaporisation of the transformation zone; comparable efficacy to LLETZ for CIN 2/3 in satisfactory colposcopy; requires laser equipment and expertise
  • Cold coagulation: Application of a thermocoagulation probe to the transformation zone; high-frequency heat treatment; effective for CIN treatment in clinic settings
• Active surveillance: For CIN 1 or low-grade smear abnormalities; most CIN 1 and some CIN 2 in young women (under 25) regress spontaneously; surveillance with repeat colposcopy at 12 months rather than immediate treatment is an accepted option for CIN 2 in this age group
• Hysterectomy: Indicated for recurrent/persistent CIN 3 or CGIN after multiple excisional treatments, especially in women who have completed their families; also primary treatment for cervical cancer beyond microinvasive stage; not appropriate as first-line treatment for CIN
• HPV vaccination: The nine-valent HPV vaccine (Gardasil 9) prevents infection with HPV strains 16, 18, 31, 33, 45, 52, and 58 — collectively responsible for approximately 90% of cervical cancers. While not a treatment for existing CIN, vaccination in treated patients (even post-conization) reduces the risk of HPV recurrence and CIN recurrence — an important secondary prevention measure